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ABSTRACT
The result of applying the Neurite Orientation Density and Dispersion Index
(NODDI) algorithm to improve the prediction accuracy for patients diagnosed with
MCI is reported. Calculations were carried out using a collection of 68 patients (34
control and 34 with MCI) gathered from the Alzheimer’s Disease Neuroimaging
Initiative database (ADNI). Patient data includes the use of high-resolution
Magnetic Resonance Images as with as Diffusion Tensor Imaging. A Linear
Regression accuracy of 83% was observed using the added NODDI summary
statistic: Orientation Dispersion Index (ODI). A statistically significant difference
in groups was found between control patients and patients with MCI with a power
0.96. In order to confirm performance, comparison of accuracy of prediction
without the use and with the use of the ODI values is also presented. The impact of
this increase in accuracy on the early detection of MCI is also presented. Results
show a 4.68% increase in prediction accuracy through the inclusion of the ODI
values. Future work includes the use of tractography to better locate the specific
area of interest. Increasing the cohort would also add validity to the results in this
paper. Expanding the number of tracts utilized in this study would also validate the
use of the NODDI algorithm to detect neurological deterioration in tracts
associated with memory. The inclusion of more complex prediction models would
also add possible increases in performance in modeling patients with MCI.
Key Words: Mild Cognitive Impairment, Computer Vision, Diffusion
Compartmental Imaging, NODDI, Alzheimer's Disease
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INTRODUCTION
Mild Cognitive Impairment is defined as cognitive dysfunction without functional
disability and this entity is believed to be an early stage of degenerative brain
disorder that progresses to dementia. Dementia is a syndrome characterized by
cognitive decline in one or more areas of cognition including memory and that
cognitive decline must be characterized as being enough to interfere functioning,
activities necessary to conduct the day to day life of the patient (Jalbert, Daiello, &
Lapane, 2008; Lyketsos et al., 2006). Dementia can result from a spectrum of brain
diseases that include Alzheimer’s Disease, vascular dementia, Parkinson’s dementia,
all of which have cognitive and functional disability.
Alzheimer’s Disease (AD) is a fatal disease defined as the global deterioration of
memory and other cognitive domain (Jalbert et al., 2008). The prevalence of
Alzheimer’s tends to increase with age with an occurrence of 1 in 1,000 people
between the age of 60-64 and 25 per 1,000 for those above the age of 85 developing
the disease (Jalbert et al., 2008; van Duijn, 1996). 1 to 2 percent of healthy adults
progress to developing Alzheimer’s Disease each year (Bischkopf, Busse, &
Angermeyer, 2002). For patients with Mild Cognitive Impairment the chance of
conversion is much higher at 10 to 15 percent per year (Bischkopf et al., 2002;
Knopman & Petersen, 2014).
Mild Cognitive Impairment (MCI), as opposed to Alzheimer’s, is more subtle. MCI
is defined as an in-between state where the patient has cognitive limitations but
functionality is generally intact but there may be subtle difficulties in functioning.
This distinction does not lie under the definition of dementia, but still remains to
inhibit the patient’s day to day life (Petersen, Doody, et al., 2001; Petersen, Stevens,
et al., 2001; Rivas-Vazquez, Mendez, Rey, & Carrazana, 2004). The general criteria
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for the diagnosis of MCI can be broken down into 5 points taken from Petersen et
al. (1999):
• Patient reports complaints of memory issues, which would be corroborated by
a trusted third-party.
• Difference from the age norm of 1.5 standard deviations on a memory
impairment test.
• No other issues in cognitive functioning.
• Does not meet the criteria for Dementia.
• Ability to perform day-to-day functioning including driving a car.
Mild Cognitive Impairment and Alzheimer’s Disease currently affect 16 million and
5.1 million people world-wide respectively. The number patients diagnosed with
Alzheimer's disease is estimated to rise to 13.2 million by 2020 and according to
Brookmeyer, Johnson, Ziegler-Graham, and Arrighi (2007) by 2050 1 in 85 people
will be living with Alzheimer’s disease. This increase can be reduced through the
practice of early detection and therapies. If early intervention can cause a 1 year
decrease in the onset of the disease an estimated 9.2 million fewer cases will occur
by the year 2050 (Brookmeyer et al., 2007).
Current best practices for diagnosing MCI in a clinical setting involves conducting
a thorough assessment of a subject’s overall physical and cognitive health (Albert et
al., 2011). This includes a number of examinations primarily focused on excluding
alternative diagnoses through a review of a patient’s medical history, diagnostic
questionnaires, and cognitive evaluation (Neugroschl & Wang, 2011). The most
common early difficulty is memory dysfunction. One of the most challenging and
sensitive measures is list learning and the most commonly used measure is the
RAVLT (Rabin et al., 2009). Ultimately as AD progresses other cognitive domains
are involved and a screening measure such as the Montreal Cognitive Assessment
9

(MoCA). Although short, it is used to describe the severity of dementia and surveys
multiple cognitive domains. These measures include items sensitive for memory and
hence can be used to detect MCI but is relatively less sensitive to memory
dysfunction than RAVLT. Whereas there is a general consistency in the types of
information leading to a diagnosis, not all people with symptoms of MCI progress
to AD and hence additional imaging and other biomarker data are being incorporated
in research diagnosis with the goal of clinical use.
One approach to improving the early detection of preclinical AD is to focus detecting
the earliest degenerative changes in the medial temporal lobe (MTL). This region is
responsible for memory. Previous studies have demonstrated correlations between
memory ability and MRI volume (Moradi, Hallikainen, Hanninen, Tohka, &
Alzheimer's Disease Neuroimaging, 2017). Because AD degeneration is
progressive, one would expect that there would be longitudinal change in the
structural differences between MCI and healthy older adults.
Combining minimally invasive neuroimage-based measures of localized structural
changes in the brain over time with other cognitive measures appears promising as
the basis of a more effective MCI diagnostic approach than is currently available.
This lack of combination in the field provides us with a technical gap in the current
literature that we wish to address in this report. Whereas there have been multiple
studies of MTL atrophy, white matter changes in the MTL have not been extensively
studied (Goldman et al., 2017; Wen et al., 2019).
Neuroimage-based analysis includes the use of systems that that model the
intricacies of the brain’s internal structure and architecture. From these models,
summary statistics are generated. These statistics are then used to further analyze
group differences. One such analysis presented in this report is Neurite Orientation
Density and Dispersion Index (NODDI). NODDI produces a summary statistic that
10

characterizes the orientation dispersion of axon bundles. Analysis from NODDI
utilizes shape distributions that closely resembles the shape and make up different
types of tissues found in the brain. The analysis and application of this algorithm is
presented in this report.

BACKGROUND
The brain changes of AD appear about a decade before the symptoms appear. MCI
is a transition stage when there is cognitive dysfunction detectable by
neuropsychological testing but before the progression to the disabling functional
incapacity of Alzheimer’s dementia (Bateman et al., 2012; Golomb, Kluger, &
Ferris, 2004; Roberts et al., 2014). During this period the brains of people with
neuropathology is deteriorating at a rate greater than those with healthy brains.
Diagnosing at or before the complete deterioration of the brain is important to the
longevity of the patient and the impact on the medical system (Brookmeyer et al.,
2007).
Clinical Diagnosis
The current clinical diagnostic criteria for Mild Cognitive Impairment primarily
focuses on whether the patient experiences cognitive declines but functional
decline in everyday life is minimal (Albert et al., 2011). Examples of difficulty
functioning include writing checks, shopping alone, playing a game, making a cup
of coffee, etc. and whether these tasks have been inhibited by any sort of memory
issue (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982; Teng et al., 2010).
Neuropsychological tests are critical for diagnosis. Whereas memory is typically
the earliest symptom of AD, other cognitive domains can be diminished including
language, attention and mental control, and visuospatial functioning.
A variety of paper and pencil neuropsychological tests are typically used. One such
test which this project utilizes is Rey Auditory Verbal Learning Test, or RAVLT
11

(Schmidt, 1996). RAVLT, originally created by Andre Rey, a Swiss psychologist,
was developed to assess verbal memory in patients 16 and older. RAVTL has
shown through multiple studies to play a significant role in the early detection of
early onset Alzheimer’s (Estevez-Gonzalez, Kulisevsky, Boltes, Otermin, &
Garcia-Sanchez, 2003; Moradi et al., 2017). Brain volume has also shown to be a
predictor of a patients RAVLT score with a has been shown to be a predictor for
brain volume as detailed by Moradi et al. (2017). For more information regarding
the intricacies of RAVLT and how it is run please refer to Appendix A.
The second test considered in this project is MoCA or Montreal Cognitive
Assessment. MoCA, created in 1996 by Ziad Nasreddine, a Canadian neurologist,
was specially designed for the early detection of Alzheimer’s (Neugroschl &
Wang, 2011) and has shown to be a highly sensitive screening measure that briefly
surveys multiple cognitive domains including memory (Nasreddine et al., 2005).
Whereas memory decline is the most common domain affected early in AD, in
some subtypes of AD other domains are affected hence a global screening measure
is an important additional measure. Because AD patients often lack insight into
their functional difficulties and have deficits in several domains, a score on MoCA
that is too low is also a warning sign that the patient has progressed beyond the
stage of MCI to AD. For more information regarding the cut offs and ranges of
different stages, please refer to Appendix B.
Diagnosis Using Neuroimaging
Although these tests have shown to be decent predictors of future progression to
AD, they exhibit high rate of false positives, which warrants exploring other
options for diagnostic tests. Having convergent data from neuroimaging can
increase accuracy of the diagnosis. Historically clinicians relied on postmortem
analysis to identify the AD brain pathology; however, presently PET identifies
12

both tau and amyloid pathology. Another such technology is Magnetic Resonance
Images (MRI) which has the advantage of not requiring injection of radioactive
tracers like PET. MRI uses powerful magnets to change the direction of spin of
hydrogen atoms in the patient’s bodies. Some of the hydrogen atoms will align to
the new magnetic direction imposed. Of these newly facing directions exist some
hydrogen atoms that face in opposing directions to their local space’s magnetic
direction. This change in direction is then interrupted using powerful radio signals
which then causes these standouts to align back to the herd’s original direction.
This sudden change releases energy which is then read by the detector facing the
patient. The energy is then converted to digital images. These images provide a key
point in the examination of the flow of water in the brain of the patient. Depending
on the way the MRI is created, different brain tissues have different values,
displayed to clinician as brightness or intensities. This information is clinically
important and can be compared to learn about the locations of the brain and
integrity of its functioning. With sophisticated analytic techniques that compare the
locations of the brain both within and across, information researchers can derive
additional insights.
This project relies on two types of images: structural T1 weighted images, and a
Diffusion Weighted Image (DWI). On a structural, T1 image, the surface of the
brain (cortex, grey matter) is grey and underneath the cortex the brain appears
white (denoted white matter). This difference in intensity is critical information
about the role of those brain regions. Information regarding grey and white matter
can be found in Appendix C.
Diffusion Weighted Images are a different kind of image that instead is sensitive to
white matter tracts. Typically, white matter is organized as groups of axons or
fibers tracts and to the extent those fibers are healthy/intact and/or the brain region
13

that DWI will vary in intensity. The technique depends on the fact that DWI is
sensitive to the degree to which water diffuses along these axons or fiber tracts.
Variation in diffusivity can be thought of conceptually as water moving along a
straw. Movement on the outside of the straw is unrestricted this is coined as “Free
Diffusion”. Much like the walls of a straw, water does not diffuse from the outside
to the inside of the straw. DWI thus generates an image that varies in Free
Diffusion and Diffusion Restriction. Included with this image is two metadata
points that characterize the gradient’s strength and timing at the moment of
acquisition; this is included as a “b-value”. The gradient directions at said time is
also included as a “b-vector”. An example of such an image can be seen in Figure
1. The image contains a processed Diffusion Weighted Image. Areas of diffusion
restriction are indicated through bright white intensities, whereas areas with less
are darker in intensity.
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Figure 1: Diffusion Weighted Image Example

Free diffusion is shown as bright white spots on the image and indicates the ability
for water in that sector to freely diffuses in any direction. Conversely, diffusion
restriction indicates limited diffusion in that area and as a result the intensity is
lower.
The field studying AD has focused on measuring grey matter volume, typically in
the hippocampus and related medial temporal lobe (MTL) structures and less so on
white matter fiber tract degeneration, hence DWI has been less frequently applied
in the prediction of MCI/Alzheimer’s (Miller et al., 2015).
Whereas DWI represents brain locations in terms of their diffusivity, to represent
fiber tracts involves complex analyses. Diffusion Tensor Imaging (DTI) is a
method of analysis that uses water diffusion to map, detect, and detail tracts of
15

axons, the long, glia encased fibers that connect the bodies of neurons (grey
matter).
Diffusion Tensor Imaging
DTI analysis was originally proposed by Peter Basser (Basser, Mattiello, &
LeBihan, 1994a, 1994b) and relies on the concept of a diffusion tensor. An image
analyzed by Diffusion Tensor Imaging contains a multitude of points called voxels
(or volumes in 3d space). Each of these voxels in the brain model either one of
three types of tissues in the brain: white matter, grey matter, and cerebral spinal
fluid. DTI analysis of these voxels provide a general model of inherent
characteristics of the tissue analyzed. In-order to produce this general model a
series of processing steps needs to occur and, depending on the source of data, can
be prone to errors as a result much preprocessing needs to take place (Soares,
Marques, Alves, & Sousa, 2013). These steps are detailed later in the Methods
section. More information regarding the background of diffusion tensor imaging is
included in Appendix D.
Diffusion Tensor Imaging’s main parameters: Mean Diffusivity (MD) and
Fractional Anisotropy (FA) have seen use in predicting atrophy among patients
along the spectrum of degeneration. Selnes et al. (2013) utilizes DTI in a way to
further predict, using regression, atrophy among patients with subjective and mild
cognitive impairment. Selnes et al. (2013) found, through a targeted study in the
medial temporal lobe, that MD and FA were significantly associated with atrophy
(p < 0.05). For the regression analysis, MD was found to be able to predict atrophy
whereas FA was not.
In Bozzali et al. (2002) FA was found to be a statistically significant difference
between the controls and AD group (p < 0.01). The areas of interest that produced
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the lowest p value includes: the corpus callosum, frontal, temporal, and parietal
lobe.
Although these statistics have seen wide use, DTI is not without its pitfalls. There
is a general recognition that in brain locations where postmortem dissection
identifies that densely packed fiber tracts cross or axonal bundles join, the results
of analysis conducted in these areas are ambiguous. Because DTI works on a voxel
per voxel basis these overlaps hinder the analysis of Fractional Anisotropy
(Tournier, Mori, & Leemans, 2011).
Technical Gaps
When using DTI models, a lot of key information is lost through its ambiguity. Inorder to address this difference in tissue modeling a multi model method must be
used, one for each type of tissue. This multi model method, otherwise known as
Diffusion Compartmental Imaging, provides a deeper insight into those regions
that might be hindered through a flat analysis of the entirety of the brain. To close
this technical gap, we utilize this method in conjunction with available cognitive
tests including RAVLT and MoCA to provide a robust implementation. For more
information and background regarding Diffusion Compartment Imaging please
refer to Appendix E.

APPROACH
Data
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) database founded by
Principle Investigator Michael W. Weiner, MD in 2003 was the primary supplier of
Data utilized in this project. The supplied data contains that of a multitude of
mediums including Magnetic Resonance Imaging (MRI), clinical assessments,
neuropsychological assessments, Positron Emission Tomography (PET), and
biological markers. The intent of the project is to test the viability of these mediums
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in the pursuit of measuring the progression of Mild Cognitive Impairment (MCI)
and early Alzheimer’s disease (AD).
The database acts as a hub for a variety of studies related to Alzheimer’s and contains
several patients who are on the spectrum between normal cognition (NC) and
dementia.
The database is primarily broken up into 4 participant stages 1, GO, 2, and 3 with 3
being the focus of attention for this project. ADNI3 is the latest in the line of studies
starting from 2016 onward and concluding in 2022. This cohort includes several
patients including 133 elderly controls, 151 patients with MCI, and 87 patients with
Alzheimer’s disease.
Included in the ADNI study are a wide variety of imaging types. Of those types this
project focuses on two types: Structural and Diffusion Imaging.
Structural Imaging
The primary purpose of Structure Imaging (T1) is to visualize the entirety of the
brain and produce clear delineation of tissue types. This includes highly detailed and
highly contrasted images that convey the internal structures of the brain. The primary
way of acquiring this structural imaging is with magnetic resonance imaging (MRI).
This type of imaging includes T1 and T2-weighted images. Our study primarily
focused on T1 images. This type of imaging removes variations in the resulting
image of the brain and provides a high amount of resolution for clearer analysis (M
Symms et. al.).
The use of this type of image in our methods provides for a greater ability to segment
portions of the brain known as white matter, grey matter, and cerebrospinal fluid
(CSF). Through this we can clearly see the differentiation between the three and as
such generate masks related to these areas. As detailed in our analysis methods, this
18

is a pivotal implementation that gives us the ability to extract out a specific portion
of the brain for use in the later analysis. Specific to the T1 image utilized, we focused
on using ones generated through the 3D Magnetization-prepared rapid gradient-echo
(MPRAGE) sequence. MPRAGE has shown to be well-established across studies
over a period as well as studies that occur at different sites or labs (Falkovskiy et.
Al). MRPAGE also provides high contrast which allows for a clearer differentiation
between tissues (Falkovskiy et. Al).
Diffusion Imaging is the prime focus for this project and provides the underlying
data that is operated on in order to produce our summary statistic. Diffusion Imaging
is a technique used to measure the diffusion of water through the brain. This
diffusion details the motion of water molecules present in the brain. Through this
information we can identify the direction of this flow using a variety of techniques.
Cohort
The cohort analyzed consists of 34 control subjects and 34 patients diagnosed with
mild cognitive impairment. Each diagnosis of the patients was taken directly from
the ADNI3 dataset and were the result of a consensus diagnosis of experts.
Of this cohort, the distribution of age acted as a nuisance parameter for the analysis
of whose distribution is referenced in Figure 1. The distribution of controls
indicating a flatter curve than the mci patients.
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Figure 2: Age Distribution of ADNI3 Patients

The cohort also consists of a minimum of two time-series data points. Two runs
over the period of a year: one at a baseline and one at a one year follow up were
conducted.
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Figure 3: (a) MOCA score Distribution at time 0 (b) MOCA score Distribution at time 1 (c) RAVLT immediate score Distribution
at time 0 (d) RAVLT immediate score Distribution at time 1

The analysis utilized in this study is the previously described Diffusion
Compartmental Imaging (DCI). The specific algorithm utilized is Neurite
Orientation Dispersion and Density Imaging (NODDI). This method was used in
conjunction with a large number of data pre-processing and manipulation steps,
which utilize the FMRIB Software Library (FSL). FSL includes several packages
that help in the processing and analysis of MRI data. Among those packages
included, this project specifically utilized seven: fslreorient2std, BET, eddy_correct,
flirt, fast, fslsplit, and fslmaths.
The pipeline for the analysis of the patient data is detailed below.

21

Figure 4: General Analysis Pipeline

The entirety of the pipeline is broken down into three sections. The first step includes
the preprocessing and formatting of the patient data. This includes the following FSL
packages: fslreorient2std, bet, eddy_correct, and flirt. The second step, being the run
of NODDI on the pre-processed patient’s data. The last being the post-processing
step that includes the use of a variety of masking tooks such as: fslmaths and
optionally (if not done already) fslsplit.
Pre-Processing
22

The goal of this preprocessing step is to fulfill the preconditions for the analysis. The
first condition is that the patient’s data be registered correctly to MNI space. This
space refers to a known orientation and coordinate system generated from an average
of 152 images of human brains. This registration allows for the targeted analysis of
specific portions of the brain using known coordinates. The template used in this
stage is the MNI 152 average template (Brett, Johnsrude, & Owen, 2002) included
in the default FSL data.
The first step of this four-step process is to utilize the fslreorient2std tool. This tool
acts as a simple reorientation script to the MNI 152 template. It reorients it in such
a way that the brain is in the same orientation in the left and the right space and is
directly on top of the MNI template. This allows for a registration process that is
least error prone.
The second step is to utilize the BET tool also included in FSL. BET is a simple
brain extraction tool. From patients MRI and DTI, it produces an image that only
includes the actual brain itself. This is used to exclude parts of the image included
in the raw base image of the patient’s brain. These parts might include the outer
portion of the skull, the eyes, and any other part outside the scope of interest. This
result is the stripped image and is then fed into the next stage: eddy_correct.
Eddy_correct or simply eddy, is a tool for use in the correction of eddy currentinduced distortions and subject movements for diffusion imaging (Andersson &
Sotiropoulos, 2016). This tool allows for the correction of possible imperfect
acquisitions of patient’s brains during the process of collecting the diffusion of water
molecules in the brain (DTI). It “corrects for distortions by registering the individual
models to a model free prediction of what each volume should look like” (Andersson
& Sotiropoulos, 2016). These corrections allow for the use of images that would
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otherwise be error prone due to issues at the collection stage. After this stage is
complete the results are then fed to the registration stage.
The tool used for this registration stage is the flirt tool supplied by FSL (Jenkinson
& Smith, 2001) (Jenkinson, Bannister, Brady, & Smith, 2002). Flirt or FMRIB’s
Linear Image Registration Tool is a tool for automatic linear brain image
registration. Image registration is the process with which one image is transformed
from its coordinate space to another images coordinate space. This is the key point
of this section. The registration of the DTI and MRI image puts them both into “MNI
space”. MNI space is a well-known probabilistic atlas developed at the Montreal
Neurological Institute. Individual brains are reshaped or warped to match the atlas
so that overlaying them increases the likelihood that functional areas align. With this
transformation images can be analyzed together in voxel-based space rather than by
manual tracing base on the shape of different brain regions.
The atlas has been used to derive a vast number of masks or clusters of voxels that
align with prior defined brain regions. These masks can be multiplied by whole brain
images to select these regions. For example, with a binary mask in which the target
brain voxels have the value of 1 and non-target brain regions have the value of 0, a
multiplication of these images selects the target brain region eliminating all other
regions. This masking is one of the reasons for this pre-processing step as detailed
in the post-processing step. Having both images also registered in this space allows
for a consistent analysis across cohorts as all the images of the brains in this cohort
have been transformed into a common space. Once transformed the cohort’s brains
can then be reliably compared knowing that the sample space each have been pulled
from is normalized.
Analysis
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The second section of the pipeline includes the running of the NODDI algorithm.
This stage can be broken down into several sub-steps described below:

Figure 5: NODDI process

The first step being the loading of the patient data into memory. This includes the
NIFTI1 formatted Diffusion Tensor Image resulting from the previous stage, the bvalues, and the b-vectors. The NIFTI1 image format (otherwise shown as nii) is a
format that provides a wrapper around the image which includes several features.
Among these features includes the affine related to that image as well as any labels
or meta data. This type of data was read using the nibabel python package. During
this loading process the patient’s b-vectors and b-values are read into a gradient table
through the use of the DIPY package (Garyfallidis et al., 2014). This gradient table
takes in the locations of the bval and bvec files, loads, and formats them accordingly.
In this loading there are several quality checks to make sure each are valid.
Once the nii, bval, and bvec files are loaded the main package utilized then translates
that gradient table into a scheme for use in the calculation of our model. The scheme
is utilized from the dmipy package and is the main encapsulation of the data needed
to simulate and train the model (Fick, Wassermann, & Deriche, 2019). The model
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utilized in this training step is comprised of three shells: a plane ball model, and a
Watson dispersed bundle of a stick and zeppelin model. This model comprises the
Neurite Orientation Dispersion and Density Imaging (NODDI) (Zhang, Schneider,
Wheeler-Kingshott, & Alexander, 2012). The NODDI model is then fit over the
entirety of the patient’s brain. The dmipy package includes two main packages for
performance enhancing: pathos (Michael M. McKerns, 2012; Michael McKerns,
2010-) and numba.
Once the model is fitted the resulting parameters are then extracted. The primary
summary statistic this project focuses on is the ODI values or orientation dispersion
index. The ODI values are included in a range from 0.0 – 1.0 and are calculated per
voxel. Through this voxel calculation an image of the brain from these values is
generated and is then saved using the original diffusion tensor image affine. This
resulting image has the same properties as the original registered image, allowing us
to proceed to the post-processing stage.
Post-Processing
The proceeding stage after the analysis of the pre-processed images includes several
masking steps and calculations based on the resulting ODI image shown below:
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Figure 6: Flow Chart of Post-Processing Steps

The post processing step includes the extraction of the specific tract being studied
through the use of a mask. For this study we used the cingulum hippocampal tract.
This tract was pulled from an atlas included in FSL from the Laboratory of Brain
Anatomical MRI in Johns Hopkins Medical Institute (Hua et al., 2008; NagaePoetscher, 2005; Wakana et al., 2007). This atlas includes a multitude of masks
built in MNI space. Since the results of our fitted model were calculated in MNI
space this result can then be utilized to look at specific portions of the brain. Using
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fslmaths we utilize the atlas related to the cingulum hippocampal region to extract
the region of interest.
Once extracted the resulting masked image is then loaded using nibabel and the
results are then calculated using the masked average value of the region. This
resulting average is the metric utilized in our statistical study of these trails.
Modeling
Once the ODI values are extracted the resulting average of the region specified is
then added to an excel file that details the patient’s metadata. This metadata
includes the patient’s RAVLT and MoCA score. Two Linear Regression Models
are then trained for the use in predicting subjects with MCI.
The first model includes the mentioned RAVLT and MoCA scores along side the
ODI values. The values are taken at both intervals and differenced between time 0
and time 1 (baseline and a 1-year follow-up) then a product is taken between the
combination of the three differenced categories. The second model then produces
the same combination but with the exclusion of the ODI values. The second model
then serves as a benchmark to test the degree with which the inclusion of ODI
values can help predict MCI subjects.
Context
The analysis of the 73 participants (comprising patients and controls) was ran on
the San Jose State University Spartan01 High Performance Computer. The
Spartan01 contains 72 compute nodes, 2 high memory nodes, and 4 GPU nodes for
a combined number of 2152 of compute cores and 23040 GPU cores. The
Spartan01 runs slurm workload manager. Through Slurm the patients were able to
be ran concurrently across 5-6 nodes for a total of ~200 individual runs. Each run
contained ~500 megabytes of data.
28

In-order to run the patient’s data on the High-Performance Computer (HPC) the
data first needs to be transferred. The procedure for transferring the data first starts
with the downloading of the individual patient files from the ADNI server. The
individual patients contain an average of two years of data. Each year contains 2
data points: The T1 MRI and the Axial DTI image which are both DICOM
formatted image files.
Once downloaded the files require a formatting specific to this implementation
after the conversion of the DICOM file format to Nifti1 image format. This is done
by a script written for this purpose. This specific portion of the pipeline requires
manual work to accomplish. Once the script is run and the files converted to the
proper format the data must then be uploaded to a server to then be downloaded.
The server of choice for this implementation is Amazon Web Service’s Simple
Secure Storage (S3). Once uploaded the files are then downloaded using the
python client boto3.

METHOD
The first objective of the study is to test two key hypotheses. The first hypothesis is
that NODDI is sensitive to AD related abnormality and hence NODDI values
should be higher in controls than in patients with MCI (hypothesis 1). The second
hypothesis is that if NODDI detects brain degeneration from AD, and MCI patients
experience brain degeneration over the course of a year, ODI values should
decrease from baseline to year later (the study of the ability to identify an
individual with MI using longitudinal data), hypothesis 2. This hypothesis also
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quantifies the magnitude of that change to identify a target for future therapies.
What is not known is whether the degeneration is more rapid in patients than
controls.
In order to produce data comparative to this situation we focused on patients who
have been scanned at least two times with the appropriate types (T1 and DTI). This
gives us a baseline and a year follow up to work with. With this data the null
hypotheses can be tested. 73 patients were gathered in an even split between those
diagnosed with control and MCI.
In summary, we proposed that the null hypothesis in hypothesis 1 is that there
would be no difference between the control patients and the patients with MCI
over the period of one year, whereas our alternative hypothesis indicates a
statistically significant difference. The null hypothesis in hypothesis 2 is that there
is not a detectable decline over a year. This could occur if timescale is long enough
to detect a significant change. A secondary analysis may not be long enough to
measure a significant change. A secondary analysis will examine whether the
declines are greater in patients with MCI since they are undergoing a degenerative
process.
The hypotheses are tested using the results from the NODDI algorithm referred to
the Orientation Dispersion Index (ODI). ODI measures the dispersion of the axons
and models, at that voxel, the orientation (be it varying from fanned to highly
directional). The response variable consists of the a priori diagnosis of each patient
group (i.e. control or MCI).
The second objective of our study is to build on the hypothesis that the use of the
orientation dispersion index can produce group differences and as a result produce
a predictor that can improve the sensitivity in discriminating patients with mild
cognitive impairment from controls.
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The results of each being set through a series of tests in order to produce
incremental stages which would indicate the possibility of a statistically significant
declaration.
The first of these steps being a statistical analysis using an ANCOVA test of the
variables group (MCI, controls) and time (baseline, year 1). Due to the nature of
brain degradation and the age differential indicated previously, the inclusion of age
as a nuisance variable is a must in order to differentiate the group difference being
purely age. An interaction of group and time variable tests whether the groups
differ in change over time. Post hoc analyses should show that the difference
between the time points should larger in patients with MCI than with controls.
Once our analysis indicates a statistically significant result, it will be evaluated
using evaluated accuracy, receiver operating characteristic (ROC), and
precision/recall values.

RESULTS
For our experiment the data gathered was ran through an Analysis of Covariance
(ANCOVA) with a combination of time point (baseline, year 1) and diagnosis
group (MCI, controls). A statistically significant t-test confirmed that individuals
in the MCI group were older than individuals in the control group, age was
included in the ANOVA as a nuisance variable/covariate.
Experiment One
We sought to analyze the differences between the two diagnosis groups. This
group difference is seen to be the most sensitive. In this case, we sought to confirm
this through using the ODI values resulting from the NODDI calculation. With
group as the effect this resulted in a statistically significant indication as show in
Table 2.
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Repeated Measures Analysis of Variance with Effect Sizes
Effect and Powers
p
group 0.000325

Observed power (alpha=0.05)
0.961

Table 1: Observed Statistical Power of the Experiment 1

In the case of the statistical experiment 1 the null hypotheses can be soundly
rejected with an observed power of 0.961 and a p-value < 0.05. As a result, it can
be postulated that through NODDI analysis there exists a large difference between
two groups. As the null hypotheses has been rejected verification can now
commence.
The intent of the verification was to interrogate the group difference further. Using
a regressor we intend to show the predictive power of this group difference. The
prediction method we selected was a linear regression model. In order to indicate
practicality, the use of the ODI value of each subject combined with the results
other tests would prove that the combination could provide an increase in accuracy
over use without.
The combination chosen was using the two tests previously described: RAVLT and
MOCA. A sample size of 140 was produced and a linear regression model was
trained with an equation shown in figure 8.
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Figure 7: Regression Equation of Delta Values

The combined results produce an accuracy that beats current clinical evaluations
with RAVLT by itself being 64% (Wood, Moodley, Lever, Minati, & Chan, 2016)
and MOCA having a specificity of 70-73% (Dautzenberg, Lijmer, & Beekman,
2020; Masika, Yu, & Li, 2020).
This equation utilizes a delta for the ODI values, MOCA, and RAVLT over one
year. Each age variable represents the individual ages of the patients pulled from
ADNI. Results of this predictor for classification is detailed in table 4.
Accuracy

ROC AUC

Average
Precision

83.08%

0.98

0.74

Table 2: Results of Regression Equation with Delta Values

The results of the model include an increased accuracy as well as an increased
ROC AUC. The average precision has decreased 0.08. The ROC curve and the
recall/precision curve have shifted even further to their desired positions.
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Figure 8: ROC curve for Regression Equation with Delta Values
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Figure 9: Recall/Precision for Regression Equation of Delta Values

In order to verify that this new equation’s accuracy is contributed to the ODI
values, testing without the ODI values included in the resulting equation resulted in
the tests shown below:
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Figure 10: Verification Regression Equation without Delta ODI Values

In this new equation the Delta ODI values was removed, and a new linear
regression model was trained. The overview of the performance of this model is
shown in table 5.
Accuracy

ROC AUC

Average
Precision

78.46%

1.0

0.69

Table 3: Classification of results on model excluding Delta ODI

The accuracy has reduced 4.62 percent. The area under the curve has increase 0.02
and the average precision has decreased 0.05. This result shows a contribution via
the inclusion of the ODI values.
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Figure 11: ROC Curve for Regression without Delta ODI Values
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Figure 12: Precision/Recall of Regression Equation without ODI Values

Hypothesis 2: Degeneration
In the second experiment we sought to confirm a change over time in each
diagnosis group. Through the use of an ANCOVA we analyzed the effect of both
time and group and found that the degeneration experienced by the MCI group was
not of a statistically significant difference of the control group. This resulted in a
small power (p-value > 0.05), as shown in Table 4.
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Repeated Measures Analysis of Variance with Effect Sizes
Effect and Powers
P

Observed power (alpha=0.05)

TIME*group 0.306

0.174

Table 4: Power of Group Differences Over Time

Our alternative hypothesis states that there was a statically change over time. We
observed no such change in this cohort.

DISCUSSION

The most robust finding of our study is that ODI values were lower in patients with
MCI than those in the control group, confirming hypothesis 1, which states that
this value is sensitive to abnormality in the medial temporal lobe. A linear
regression equation further interrogated whether using ODI as a metric improves
the diagnosis accuracy. The diagnostic ability of the trained classifier was
evaluated using a ROC curve, accuracy, and average precision. Neither ODI
change over one year or group differences between ODI changes were statistically
significant.
The findings of the study which confirmed hypothesis 1 was validated using linear
regression. Two models were trained on the dataset generated: one trained with the
inclusion of the ODI values and one without. Through the inclusion of the ODI
values, the model showed a marked improvement in accuracy as compared to the
model trained without.

CONCLUSION
Our study demonstrates that NODDI is an excellent method of differentiating
between the diseased and healthy individuals. Its ability to further characterize the
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different tissues of the patients allows for a more in-depth and robust analysis of
the patient cohort.

FUTURE WORK
Whereas longitudinal change in ODI was too small to detect a future reanalysis of
data over two or three years may reveal a change. An examination of the raw
difference scores suggested that the patients with MCI may have experience so
much decline that their year 1 may reflect a floor effect in which those scores may
not have farther to fall and the sensitivity of this NODDI analysis may be earlier in
the disease state. For example, the analysis may be useful in identifying which of
the healthy controls will later progress.
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APPENDICES
APPENDIX A
RAVLT
During the RAVLT the examiner reads a list of words and after hearing the list of
words, the patient needs to repeat those words back. After several trials of this
immediate recall, there is a 20-minute delay and then the patient is asked to recall
the items on the list they previously rehearsed.
RAVLT is broken into two sections: Immediate and Percent Forgetting. A patient’s
Immediate recall score is the sum of all the items correctly recalled on all the five
immediate recall trials. The delayed recall is the number of items recalled after this
delay. An assumption is that with brain atrophy associated with degeneration
smaller brain regions are associated with worse functioning. This key finding is
due to the role the medial temporal lobe plays in memory and shows the power of
RAVLT to indicate a decline in the memory portion of the brain thus providing a
powerful predictor in early Alzheimer’s.
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APPENDIX B
MoCA
For reference, a patient classified as one with normal cognition will have a score of
26 or over. A cut-off score of 18 is considered to this threshold between patients
with MCI from AD, whereas the average score for MCI is 22 with a range between
19-25 and 16 for mild AD with a range of 11-21 ("FAQ | MoCA Montreal Cognitive Assessment," 2020). When a more intact level on this range is recorded
it acts as confirmation that the patient is still at the stage of MCI.

APPENDIX C

Grey and White Matter
Grey matter is comprised of neuron bodies and white matter is comprised of the
connections between neurons or axons. These white matter brain regions appear to
be white because the axonal fiber tracts are supported and insulated by glia that
surround the axons. Much like an electric wire conducts more effectively because
it is surrounded by insulation, neurons function more effectively when the axons
that need to conduct brain signals (action potentials) are insulated by glia.
A white matter fiber tract is a group of axons. The groups travel between different
brain regions which suggests that there is communication between these brain
regions. This provides an important clue about how the regions function and how
brain pathology disrupts this process.

APPENDIX D
Diffusion Tensor Imaging
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Diffusion Tensor Imaging processing includes a series of steps of which completes
with a tensor estimation phase. This phase uses estimation procedures like
Ordinary Least Squares in order to produce the voxel’s eigenvalues and
eigenvectors. A voxel’s diffusion tensor represents the base direction and
magnitude of the voxel at each point in the brain. These directions and magnitudes
are generated from a 3x3 symmetric matrix.
Once the tensor is estimated and the brain is modeled, different diffusion
characteristics are modeled. Of the three tissue types, white matter in the brain is
characterized by less diffusion restriction but tends to be directionally dependent
whereas grey matter tends be less directionally dependent. Lastly Cerebral Spinal
Fluid tends to freely diffuse is every direction.
These different inherent characteristics of the three tissue types make possible
modeling tracts and the directions of these voxels over a distance and leading to
analysis such as tractography that maps entire bundles of axons throughout the
brain and can give an accurate representation of the internal structure and
architecture of connections between brain regions.
Included with the tractography analysis are a variety of summary statistics
resulting from Diffusion Tensor Imaging. These statistics include two main
statistics: Mean Diffusivity (MD) and Fractional Anisotropy (FA). Analysis of
these statistics are usually done in a region of interest manor specifying the area of
the brain to study. Of these areas, higher MD models an increase of diffusion
whereas lower FA indicates and lack of cohesion in that region (Soares et al.,
2013).

APPENDIX E
Diffusion Compartmental Imaging
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Diffusion Compartment Imaging is a relatively new subset of techniques to analyze
Diffusion Weighted Images. DCI’s purpose is to utilize a complex combination of
different models, each whose purpose is analyzing voxels of different tissue types
found in the brain of which are divided up into intra-cellular space, extra-cellular
space (Zhang et al., 2012).
Extra-cellular space is mostly defined as the cellular membranes of somas and glial
cells, whereas Intra-cellular space is defined as space bounded by axonal and
dendritic membranes (Zhang et al., 2012). Each of these cellular types harkens
back to the two distinctions (free diffusion and restricted diffusion) of the tissues in
the brain and identifies the different types of restrictions present: Hindered and
Restricted. Hindered diffusion points to the pattern found in the extra-cellular
space whereas Restricted diffusion points to the intra-cellular space (Assaf &
Cohen, 2000).
The distinction between these two spaces found in Diffusion Weighted Images and
the types therein produces a model of the brain that is more complex than a
generalized model of the three types of tissues. In-order to properly analyze this
distinction a model must include these characteristics, but in what way should
these distinctions be modeled?
The Diffusion Tensor Imaging method of modeling is to build a symmetrical
tensor for each voxel. This symmetrical tensor is modeled with three threedimensional vectors representing the directions of flow usually in a single distinct
direction. This highly specific direction does not consider a possible distribution of
values over these axes.
Several implementations have been proposed to provide this distinction to better
model different types of diffusion in the brain using various shapes. These shapes
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have their own distributions and characteristics akin to different intra- and extracellular components.
One such model is the ball and stick model (Behrens et al., 2003). The distinction
between the intra-cellular and extra-cellular compartments are made using a stick
and ball representation. The stick, being a cylinder of zero radius, is used to model
the highly restrictive intra-cellular components, whereas the ball is utilized to
model the hindered extra-cellular component (Behrens et al., 2003; Panagiotaki et
al., 2012). Based on the knowledge of the intra-cellular region being highly
restricted and directional, the stick model portrays this distinction representing
each voxel to lie on a path that is geometrically restricted. The ball in this case
portrays the highly diffuse nature of the extra-cellular compartment as the direction
of diffusion is less strict in these regions.
Another model named CHARMED or Composite Hindered And Restricted Model
of Diffusion (CHARMED) utilizes an impermeable ideal cylinder whose radius
matches a gamma distribution (Assaf & Basser, 2005; Assaf, Freidlin, Rohde, &
Basser, 2004; Panagiotaki et al., 2012; Zhang et al., 2012). This idealized cylinder
represents the intra-cellular compartment. The extra-cellular compartment is
represented by a non-directionally dependent value.
A simplified version of CHARMED was proposed by Alexander (2008) which
reduces the complexity of the gamma distribution to a single radius. This keeps the
form of the cylinder for the intra-cellular representation and a shape of a Zeppelin
for use in the extra-cellular area. The introduction of the Zeppelin keeps the
directionally independent nature of the extra-cellular area but introduces a
symmetric component about an axis. Later additions were made to the CHARMED
model in the addition of another compartment: free-water. The intent of this
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compartment was to obtain the minimal model of white matter diffusion coined as
MMWMD (Barazany, Basser, & Assaf, 2009).

Figure 13: The Stick, Ball, and Zeppelin model

With each implementation the concept of a distinct shape representing the distinct
restrictions is paramount. The Ball & Stick method, plus the simplification of the
CHARMED model with a Zeppelin for the extra-cellular component represents the
crux of the next model proposed. NODDI or Neurite Orientation Density
Dispersion Index provides a combination of these models (Zhang et al., 2012).
In the case of the Intra-cellular model the highly restrictive nature is modeled using
a Watson distributed distribution of sticks. This allowed for the modeling in
instances where axons are either highly parallel to other bundles like in the corpus
callosum to instances where the intra-cellular component consists of fans and
bends as in the centrum semiovale (Zhang et al., 2012).
For the extra-cellular model, the compartment is modeled using an orientationdispersed cylinder or Zeppelin. The Zeppelin is also modeled using a Watson
distribution. Lastly, in keeping with the three types of tissues in the brain, the CSF
or Cerebral Spinal Fluid is modeled using a Ball to represent the lack of directional
dependence on the count of the diffusion for that region.
The result of the NODDI calculation, much like DTI, produces a summary
statistic: Orientation Dispersion Index (ODI). The ODI value consists of a range
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between 0 and 1 bounded by a Watson distribution which measures the dispersion
of each voxel’s orientation. A higher ODI value indicates lower diffusion at the
point of the voxel of which indicate an intact white matter tract. A decrease found
in ODI would indicate water diffusing more freely due to not being constrained by
intact white matter tracts and as a result should reflect degeneration.
Comparisons
The comparisons between the summary statistic generated by DTI and the ODI
generated by NODDI was the topic of a recent study by (Wen et al., 2019). This
study focused on a numerous amount of tract data produced through a cohort of
patients with no complications to patients with mild cognitive impairment. The key
contribution taken away from this study was the vast number of tracts studied in
their analysis. The study contained an analysis of 27 tracks of patients with earlystage Alzheimer’s disease. Of these tracks Wen et al. (2019) found that the tracks
with the highest predictive power to discriminate groups were found in the
parahippocampal cingulum, thalamic radiation, and forceps major region of the
brain.
An addition comparison between DTI, NODDI, and q-space analysis resulted with
DTI being the most sensitive in its ability to produce a characterization of the
degradation but found that NODDI and q-space still characterized the degradation.
With the a-priori analysis produced by Wen et al. (2019) we proceed with an
analysis of a variety of patients of which include an even distribution of control
and those diagnosed with MCI the goal of which is to utilize RAVLT and MOCA
as well as NODDI to produce a group difference between the two that is invariant
to possible attributes like age.
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